Scalper1 News
Vertex Pharmaceuticals (VRTX) stock fell, then rose, in morning trading Thursday as investors and analysts assessed the results of a Phase III test of its treatment for cystic fibrosis, called Kalydeco. “The study did not meet its primary endpoint,” Vertex said in its press release early Thursday. But the company also said “pre-specified subset analysis in patients 18 years of age and older showed statistically significant improvements in lung Scalper1 News
Scalper1 News